Bradanicline
Clinical data
Other namesTC-5619
Identifiers
  • N-[(2S,3R)-2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2- carboxamide
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H23N3O2
Molar mass361.445 g·mol−1
3D model (JSmol)
  • C1CN2CCC1[C@@H]([C@@H]2CC3=CN=CC=C3)NC(=O)C4=CC5=CC=CC=C5O4
  (verify)

Bradanicline (INN,[1] code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder.[2] Phase I clinical trials were completed successfully, and it was in phase II trials.[3]

In May 2011, AstraZeneca declined to exercise its right to license the compound.[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[5] It was being studied for cognitive and memory enhancement.[6]

Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013.[7] It was also discontinued for ADHD.[7]

References

  1. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 73" (PDF). World Health Organization. pp. 68–9. Retrieved 3 January 2017.
  2. ↑ "TC-5619 Cognitive Dysfunction in Schizophrenia". Catalyst Biosciences. Archived from the original on August 20, 2008.
  3. ↑ Drahl C (September 2008). "Rethinking Schizophrenia". Chemical & Engineering News. 86 (37): 38–40. doi:10.1021/cen-v086n037.p038.
  4. ↑ "Targacept retains full development rights for TC-5619". Fierce Biotech. 2 May 2011.
  5. ↑ "Targacept ends development of ADHD drug". Market Watch.
  6. ↑ "Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF). November 27, 2013.
  7. 1 2 "Bradanicline - Attenua". AdisInsight. Springer Nature Switzerland AG.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.